Alzheimer’s, a progressive neurodegenerative disease with no known cure, is one of the greatest challenges to the health and well-being of older people worldwide. The disease, which primarily affects memory, thinking and behavior, has a significant impact on individuals with it, as well as their families and caregivers.
Alzheimer’s is the most common form of dementia, accounting for approximately 60–80% of all cases. It is estimated that around 50 million people are currently living with dementia worldwide, and this number is expected to triple by 2050. An aging population and increasing life expectancy are contributing factors to this alarming increase.
Alzheimer’s disease is characterized by an abnormal build-up of proteins in the brain, leading to the formation of tangled plaques of beta-amyloid and tau proteins. These changes affect communication between brain cells, leading to a gradual decline in cognitive function.
Symptoms of Alzheimer’s can vary, but typically include memory loss, difficulty thinking and reasoning, changes in behavior, and difficulty performing daily tasks. As the disease progresses, patients may have difficulty communicating, may lose the ability to recognize loved ones, and may experience mobility problems.
Despite progress in understanding the disease, there is no cure for Alzheimer’s yet. However, pharmacological treatments and non-pharmacological treatments have been developed that can help control symptoms and improve the quality of life of patients in the early stages of the disease.
According to reports from the pharmaceutical industry, the donanumab treatment is an intravenous application that targets amyloid, a substance that forms plaques in the brain and is the prime suspect in worsening Alzheimer’s disease.
The study was carried out on more than 1,730 patients and managed to slow down decline in 35% of them compared to volunteers who received a placebo in an analysis that lasted 18 months, the laboratory reported. According to the laboratory, half had no evidence of amyloid plaques at 12 months.
Early recognition and accurate diagnosis are essential for providing adequate support to patients and their families. People experiencing changes in memory or cognitive function are encouraged to seek medical attention and undergo a complete neurological evaluation.
The fight against Alzheimer’s also requires scientific research, public education, and efforts to develop health policies that address the challenges associated with the disease. Investment in research and collaboration between academic institutions, government agencies and non-profit organizations is needed to advance understanding of this disease and find more effective treatments.
In conclusion, Alzheimer’s is a growing challenge to global health, with a significant impact on affected people and society in general. As the incidence of this disease rises, it is important to increase efforts to improve diagnosis, treatment, and support for patients and their families. Continued research and public awareness are critical to effectively addressing this issue and providing a better quality of life for those living with Alzheimer’s.